Can Stevens–Johnson syndrome occur in patients who have been taking lamotrigine for many years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Stevens-Johnson Syndrome Occur After Years on Lamotrigine?

Yes, Stevens-Johnson syndrome (SJS) can occur even after many years of lamotrigine use, though this is extremely rare—the vast majority of cases develop within the first month of therapy.

Timing of Risk

The evidence clearly shows a temporal pattern for lamotrigine-induced SJS:

  • Highest risk period: The first 5-28 days after drug initiation 1
  • Most cases: Occur within the first 8 weeks of exposure 2
  • Late-onset cases: Documented after 6 months of stable use 3

While the UK guidelines emphasize that a latent period of 5-28 days following drug initiation is the most likely timeframe for SJS/TEN development 1, case reports demonstrate that delayed-type hypersensitivity reactions can occur well beyond this window. One documented case showed SJS developing after 6 months of lamotrigine use in a patient who had no initial warning signs during the first half-year of therapy 3.

Risk Factors That Increase Susceptibility

Key factors that elevate risk at any time point:

  • Concomitant valproic acid use: The most significant risk factor, present in 19 of 38 cases in a systematic review 4
  • Rapid dose titration: Increases risk regardless of treatment duration 4
  • Genetic predisposition: HLA-B15:02 (Chinese/Southeast Asian), HLA-B31:01 (Japanese), HLA-B*44:03 (Korean) 5
  • Female sex and younger age: More common in lamotrigine-associated cases 6

Clinical Vigilance Required

Warning signs to monitor (even in long-term users):

  • Fever preceding skin manifestations
  • Mucosal erosions (oral, conjunctival, genital)
  • Flat, diffuse erythematous maculopapular rashes
  • Targetoid lesions
  • Systemic symptoms (malaise, arthralgia)

The systematic review of 38 cases showed that clinical features consistently included mucocutaneous lesions, epidermal detachment, fever, and conjunctivitis, with most patients recovering within 2-3 weeks after drug discontinuation, though two deaths were reported 4.

Immediate Management Protocol

If SJS is suspected in a long-term lamotrigine user:

  1. Discontinue lamotrigine immediately 1—this is the single most critical intervention
  2. Calculate SCORTEN within first 24 hours to predict mortality risk 1
  3. Transfer to burn center or ICU if >10% body surface area involvement 1
  4. Initiate supportive care: IV fluids, wound care, nutritional support
  5. Consider systemic corticosteroids and immunoglobulins (though evidence for efficacy remains uncertain) 4

Critical Pitfalls to Avoid

Common mistakes in long-term users:

  • Assuming immunity: Long-term tolerance does NOT guarantee permanent safety
  • Attributing symptoms to other causes: The rarity of late-onset cases may lead to diagnostic delay
  • Continuing the drug: Even a single additional dose can worsen outcomes
  • Missing concomitant drug interactions: Adding valproic acid to stable lamotrigine therapy resets the risk window

The Spanish pharmacovigilance data showed lamotrigine was the second most common antiepileptic associated with SJS/TEN reports (37 SJS, 20 TEN cases), with most occurring in the first month but not exclusively 7. Recent data from 2019-2022 shows lamotrigine emerging as an increasingly common cause, accounting for 40% of SJS/TEN cases in one burn center, particularly with off-label psychiatric use 6.

Patient Education Essentials

Counsel all patients on lamotrigine (regardless of duration) to:

  • Report any new rash, fever, or mucosal symptoms immediately
  • Understand that risk persists throughout treatment, though dramatically lower after initial months
  • Avoid restarting lamotrigine without specialized rechallenge protocols if SJS occurs 5
  • Inform all healthcare providers about lamotrigine use before starting new medications

The bottom line: While the overwhelming majority of lamotrigine-induced SJS occurs within the first month of therapy 1, 4, 7, documented cases of delayed reactions after 6 months 3 mean that clinicians must maintain vigilance throughout the entire treatment course. Any new mucocutaneous symptoms warrant immediate evaluation and consideration of drug discontinuation.

Related Questions

For an 18-year-old male who had his lamotrigine dose increased from 25 mg to 50 mg, what are the next best steps to assess the rash for Stevens‑Johnson syndrome and when should referral to the emergency department be recommended?
What is the likelihood of Stevens-Johnson syndrome occurring with lamotrigine in a patient who previously experienced Stevens-Johnson syndrome with terbinafine (Lamisil)?
In a patient taking lamotrigine (Lamictal) who develops throat pain a few days after a dose increase without fever, rash, or itching, could this be a side effect of lamotrigine or an early sign of Stevens‑Johnson syndrome?
What are the symptoms of Stevens-Johnson syndrome associated with lamotrigine (Lamictal) and when should medical treatment be sought?
What is the incidence (percentage) of Stevens‑Johnson syndrome induced by lamotrigine?
Can proton pump inhibitors (e.g., omeprazole, esomeprazole) cause palpitations in an adult patient taking a standard dose for gastritis?
How should low cortisol in a patient with a pituitary adenoma be evaluated and managed?
Can regular insulin be used for preprandial and postprandial glucose management in patients with diabetes?
What is the recommended dosing, titration schedule, monitoring parameters, and side effect considerations for lurasidone in adults with schizophrenia?
What is the difference between capillary blood glucose (CBG) obtained by finger‑stick and venous plasma glucose drawn from a vein?
Can trazodone be used safely in patients with adrenal insufficiency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.